BRAF and plasma cell myeloma: To explore the clinical and biological significance of RAS/BRAF mutations in patients with myeloma, we studied the association of RAS/BRAF mutations with a panel of parameters including laboratory data, cytogenetic aberrations, responses to therapy, and clinical outcome.